Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02650427 : A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Patients with 18 years old the day of inclusion.

- For women, a negative blood pregnancy test before inclusion is necessary. Note: this
test will be done only to women of childbearing age and non menopausal.

- HCC based on medical imaging with indication of liver resection and without
contra-indication of preoperative liver biopsy.

- Minor resection not exceeding 2 liver segments

- No cirrhosis or cirrhosis with a Child-Pugh Score Class A. Note: this score is used
worldwide to assess liver function in cirrhosis.

- Informed consent must be obtained for all subjects prior to study entry.

- Patients affiliated to health policy insurance.

Exclusion Criteria:

- Presence of HIV Infection.

- Presence of renal impairment (CrCl <60 ml / min).

- Liver function compromised (Child Pugh B, MELD score > 9)

- Indirect sign of portal hypertension (Oesophagal Varices, splenomegaly, platelet
count less than 100.000)

- A need for major hepatic resection (more than 2 segments)

- Taking digoxin (digitalis) within 6 months of starting treatment.

- History of severe hypersensitivity reaction (such as anaphylactic shock or
angioedema) to sitagliptin.

- Patients with diabetes.

- Pregnant or absence of an effective contraception for women.

- A person deprived of liberty by judicial or administrative decision, person subject
to a legal protection measure.

- Living conditions suggesting an inability to track all scheduled visits by the

- Life expectancy less than 3 months.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557